Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis-Reference-Cited by-同舟云学术

Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis

Published:2020-08-25 Issue:3 Volume:80 Page:406-408
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Kim Hanna^ORCID,Dill Samantha,O'Brien Michelle,Vian Laura,Li Xiaobai,Manukyan Manuk,Jain Minal,Adeojo Lilian W,George Jomy,Perez Maria,Grom Alexei A,Sutter Michelle,Feldman Brian M^ORCID,Yao Lawrence,Millwood Michelle,Brundidge April,Pichard Dominique C,Cowen Edward W,Shi Yinghui,Lu Shajia,Tsai Wanxia Li,Gadina Massimo,Rider Lisa G,Colbert Robert A

Funder

Intramural Research Program of National Institute of Arthritis and Musculoskeletal and Skin Diseases

Intramural Research Program of the National Institutes of Health

Intramural Research Program of National Institute of Environmental Health Sciences

Eli Lilly and Company

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference6 articles.

1. Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools

2. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

3. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

4. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative

5. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK Inhibitors - Pros and Cons Learned from Their Use in Rheumatic Diseases;Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology;2024-08-20

2. Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons;Expert Opinion on Pharmacotherapy;2024-08-12

3. JAK inhibition with tofacitinib rapidly increases contractile force in human skeletal muscle;Life Science Alliance;2024-08-09

4. Effectiveness of generic tofacitinib in idiopathic inflammatory myositis (IIM)—a retrospective analysis from Indian Myositis Registry (MyoIN);Clinical Rheumatology;2024-06-03

5. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature;Seminars in Arthritis and Rheumatism;2024-06